Monitor for the full publication of Dr. Calabrese's results later this year, as well as upcoming quarterly earnings (expected 2026 outlook range $200M-$205M revenue per prior 20-F) for any changes in CYTOGAM sales trajectory. No immediate trading catalyst from this clinical data highlight alone.
Price Chart
Executive Summary
Kamada announced positive results from an investigator-initiated study of CYTOGAM presented at the 2026 ISHLT annual meeting. The data suggest CYTOGAM use in CMV high-risk lung transplant recipients is associated with improved clinical outcomes and potential immune modulation benefits. While supportive of the product's profile, this is a press release highlighting existing clinical data, not a catalyst with quantifiable revenue impact, and represents routine scientific communication.
Key Facts
- Results from three posters on CYTOGAM (CMVIG) presented at the 2026 ISHLT annual meeting in Toronto
- Retrospective analysis showed CMV high-risk lung transplant recipients not receiving CMVIG had worse clinical outcomes vs those who received it
- Non-clinical in-vivo model suggested CMVIG blunted lung injury and improved mortality
- CYTOGAM is the sole FDA-approved immunoglobulin product for CMV prophylaxis in kidney, lung, liver, pancreas and heart transplantation
- CEO Amir London stated the data support increased product utilization for CYTOGAM
- Full results to be published later this year
Financial Impact
No financial figures or revenue guidance provided in this filing. No material dollar amount cited.
Risk Factors
- Study is investigator-initiated, not a Kamada-sponsored registrational trial — limited direct revenue impact
- Forward-looking statements about increased CYTOGAM utilization remain aspirational without commercial execution proof
- Geopolitical risks from Middle East conflicts and tariffs could affect broader operations as disclosed in the filing
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001213900-26-077360 |
| Document: ea0297771-6k_kamada.htm | 0001213900-26-077360 |
| Document: 0001213900-26-077360-index-headers.html | 0001213900-26-077360 |
| Document: 0001213900-26-077360-index.html | 0001213900-26-077360 |
| Document: 0001213900-26-077360.txt | 0001213900-26-077360 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 16, 2026 16d ago | EFFECT | $8.19 $8.77 | ▲ +7.08% | ▲ +4.52% | $8.20 (+0.12%) |
Sep 10, 2026 22d ago | 6-K | $7.99 $8.67 | ▲ +8.51% | ▲ +9.01% | $8.20 (+2.63%) |
Sep 3, 2026 29d ago | Press Release | $8.54 $8.31 | ▼ −2.69% | ▼ −1.48% | $8.20 (−3.98%) |
Sep 3, 2026 29d ago | 6-K | $8.54 $8.31 | ▼ −2.69% | ▼ −1.48% | $8.20 (−3.98%) |
Aug 17, 2026 6w ago | 6-K / PRESS-RELEASE | $7.76 $8.43 | ▲ +8.63% | ▲ +9.82% | $8.20 (+5.67%) |
Aug 12, 2026 7w ago | 6-K | $6.88 $7.89 | ▲ +14.68% | ▲ +15.12% | $8.20 (+19.19%) |
Aug 5, 2026 8w ago | 6-K | $7.14 $7.26 | ▲ +1.68% | ▲ +0.47% | $8.20 (+14.85%) |
Aug 5, 2026 8w ago | 6-K | $7.18 $6.88 | ▼ −4.18% | ▼ −4.53% | $8.20 (+14.21%) |
Jul 20, 2026 10w ago | 6-K | $7.09 $7.06 | ▼ −0.42% | ▲ +0.00% | $8.20 (+15.66%) |
Jul 13, 2026 11w ago | 6-K | $7.17 $7.05 | ▼ −1.67% | ▼ −0.89% | $8.20 (+14.37%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access